83P A single-arm meta-analysis of the safety and efficacy of erdafitinib in patients with FGFR-altered urothelial carcinoma and solid tumors previously treated with systemic therapy
Erdafitinib is a pan-FGFR inhibitor approved for treating locally advanced or metastatic urothelial carcinoma and solid tumors with FGFR alterations after previous systemic therapy. We aim to evaluate its safety and efficacy in patients with FGFR-altered solid tumors, including urothelial carcinoma.
Authors
- Mahmoud Elsawy (ORCID: https://orcid.org/0000-0001-9872-2471)
- Amr Ehab El‐Qushayri (ORCID: https://orcid.org/0000-0002-0967-797X)
- Mohamed Arafa (ORCID: https://orcid.org/0000-0003-0107-8857)
- Ahmad R. Al‐Qudimat (ORCID: https://orcid.org/0000-0003-1161-7244)
- Muhamad Amin Rifai (ORCID: https://orcid.org/0000-0002-1598-7966)
- Ahmed Ibrahim Ahmed (ORCID: https://orcid.org/0000-0002-5886-7999)
- Laila Shalabi (ORCID: https://orcid.org/0000-0001-7334-9711)
- M. Asif (ORCID: https://orcid.org/0009-0000-2165-4589)
- Sofian Zreigh
- Ahmed Al Sakini
- Yaqeen Alsheyab
Institutions
- University of Jordan (JO)
- Alfaisal University (SA)
- University of Baghdad (IQ)
- Al-Azhar University (EG)
- Hamad General Hospital (QA)
- Ankara Yıldırım Beyazıt University (TR)
- Shebin Teaching Hospital (EG)
- Hamad Medical Corporation (QA)
- Alexandria University (EG)
- Minia University (EG)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104242
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00